Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies
Obesity · 2025
DOI: 10.1002/oby.24329 ↗At a glance
Klinische Studie (Phase II) in Obesity, 2025. Written by Birgitte S Wulff and 8 co-authors. Institution: Novo Nordisk A/S, Måløv, Denmark. Major MEDLINE topics: Peptide YY, Obesity, Glucagon-Like Peptides, Peptide Fragments. Cited 19 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Novo Nordisk A/S.
Abstract (original language)
Objective
The hormone peptide YY (PYY; cleaved into Y 2 ‐selective form PYY 3‐36 ) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This series of studies investigated a novel long‐acting PYY 3‐36 analogue (PYY1875) alone and as an add‐on to semaglutide for treatment of obesity.
Methods
Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.
Results
PYY1875 induced additional body weight loss in semaglutide‐treated obese rats. In the phase 1 study, all doses of PYY1875 alone and coadministered with semaglutide were tolerated. In the phase 2 study, a modest but not clinically meaningful treatment effect of PYY1875 1.0 mg versus placebo as an add‐on to semaglutide 2.4 mg was observed. However, gastrointestinal‐related adverse events were common with the 1.0‐mg PYY1875 dose, and the 2.0‐mg PYY1875 dose escalation regimen was not tolerated (both as add‐ons to semaglutide).
Conclusions
PYY1875 showed modest efficacy as an add‐on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Novo Nordisk A/S, Måløv, Denmark.
- Novo Nordisk A/S, Søborg, Denmark.
- Celerion, Tempe, Arizona, USA.
- Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID profiles: Birgitte S Wulff, Katrine Kirkeby, Anders Rasmussen Rinnov, Riia K Sustarsic, Søren Østergaard, Patrick M O'Neil
Funding
- Novo Nordisk A/S
Cite
APA
Wulff, B. S., Chambers, A. P., Osorto Contreras, C. K., Kirkeby, K., Rinnov, A. R., Sustarsic, R. K., Østergaard, S., Laabs, J. E., & O'Neil, P. M. (2025). Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity. https://doi.org/10.1002/oby.24329
Vancouver
Wulff BS, Chambers AP, Osorto Contreras CK, Kirkeby K, Rinnov AR, Sustarsic RK, et al. Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies. Obesity. 2025. doi:10.1002/oby.24329
BibTeX
@article{Wulff2025,
author = {Wulff, Birgitte S and Chambers, Adam Paul and Osorto Contreras, Cynthia Karenina and Kirkeby, Katrine and Rinnov, Anders Rasmussen and Sustarsic, Riia K and Østergaard, Søren and Laabs, John E and O'Neil, Patrick M},
title = {Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24329}
}
EUVIMED